Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Parkinsonism & Related Disorders

• Publication date

  2013-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.parkreldis.2012.11.020PMID 23287001PMCID PMC3661282
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Significance of Continuous Dopaminergic Stimulation in the Treatment of Parkinson’s Disease

  2012cited by this paper
• Levodopa–carbidopa intestinal gel for treatment of advanced Parkinson’s disease

  2011cited by this paper
• Parkinson's disease symptoms: The patient's perspective

  2010cited by this paper
• Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease

  2010cited by this paper
• The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson's disease.

  2009cited by this paper
• Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease

  2009cited by this paper
• Homocysteine levels after acute levodopa intake in patients with Parkinson's disease

  2009cited by this paper
• Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson's disease.

  2009cited by this paper
• Apomorphine and levodopa infusion therapies for advanced Parkinson’s disease: selection criteria and patient management

  2009cited by this paper
• Bilateral Deep Brain Stimulation vs Best Medical Therapy for Patients With Advanced Parkinson Disease: A Randomized Controlled Trial

  2009cited by this paper
• Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial.

  2009cited by this paper
• Role of homocysteine in the treatment of Parkinson's disease

  2008cited by this paper
• Levodopa: Past, Present, and Future

  2008cited by this paper
• Neuropathy as a potential complication of levodopa use in Parkinson's disease

  2008cited by this paper
• Continuous levodopa for advanced Parkinson’s disease

  2007cited by this paper
• Minimizing endoscopic complications in enteral access.

  2007cited by this paper
• A randomized trial of deep-brain stimulation for Parkinson's disease.

  2006cited by this paper
• Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications.

  2006cited by this paper
• Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson’s disease

  2006cited by this paper
• Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease

  2005cited by this paper
• Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study.

  2005cited by this paper
• A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.

  2005cited by this paper
• Impact of the motor complications of Parkinson's disease on the quality of life

  2005cited by this paper
• Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.

  2005cited by this paper
• Effects of dyskinesias in Parkinson's disease on quality of life and health‐related costs: a prospective European study

  2005cited by this paper
• Levodopa in the treatment of Parkinson's disease: Current controversies

  2004cited by this paper
• Avoidance of dyskinesia

  2004cited by this paper
• Complications of enteral access.

  2003cited by this paper
• Optimizing Levodopa Pharmacokinetics: Intestinal Infusion Versus Oral Sustained-Release Tablets

  2003cited by this paper
• Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study.

  2000cited by this paper
• A Home Diary to Assess Functional Status in Patients with Parkinson's Disease with Motor Fluctuations and Dyskinesia

  2000cited by this paper
• Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations

  1998cited by this paper
• Erratic gastric emptying of levodopa may cause “random” fluctuations of parkinsonian mobility

  1988cited by this paper
• The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport.

  1984cited by this paper
• Treatment of parkinsonism with levodopa.

  1969cited by this paper

• Therapeutic innovations for the symptomatic treatment of Parkinson's disease: focus on technology-based therapies.

  2025cites this paper
• Endoscopic Complications Are More Frequent in Levodopa–Carbidopa Intestinal Gel Treatment via JET-PEG in Parkinson’s Disease Patients Compared to Nutritional PEG in Non-Parkinson’s Disease Patients

  2024influential citation
• Effect of DOPA decarboxylase inhibitor supplements on the incidence of urinary tract infections in Parkinson's disease patients: A systematic review and meta-analysis of randomized controlled trials.

  2024cites this paper
• Therapeutic effect of an inhaled levodopa dry powder formulation on off episodes in patients with Parkinson’s disease

  2024cites this paper
• Abdominal pain in Parkinson’s disease

  2023cites this paper
• Optimised endoscopic access for intrajejunal levodopa application in idiopathic Parkinson's syndrome

  2023cites this paper
• Intrajejunale L-Dopa-Applikation bei der Parkinson-Krankheit: Optimierung der PEG-Anlage

  2023cites this paper
• Why do ‘OFF’ periods still occur during continuous drug delivery in Parkinson’s disease?

  2022cites this paper
• Pharmacokinetics of Intravenously (DIZ101), Subcutaneously (DIZ102), and Intestinally (LCIG) Infused Levodopa in Advanced Parkinson Disease

  2022cites this paper
• Leczenie zaawansowanej choroby Parkinsona — rekomendacje Polskiego Towarzystwa Choroby Parkinsona i Innych Zaburzeń Ruchowych

  2022influential citation
• Frequency of adverse events in Levodopa‐carbidopa intestinal gel treatment: a retrospective real life study.

  2022cites this paper
• Multicenter study of levodopa carbidopa intestinal gel in Multicenter study of levodopa carbidopa intestinal gel in Parkinson's disease: the Turkish experience Parkinson's disease: the Turkish experience

  2022cites this paper
• 24-Hour Levodopa-Carbidopa Intestinal Gel: Clinical Experience and Practical Recommendations

  2021cites this paper
• Current Knowledge on the Background, Pathophysiology and Treatment of Levodopa-Induced Dyskinesia—Literature Review

  2021cites this paper
• Parkinson’s Disease: Personalized Pathway of Care for Device-Aided Therapies (DAT) and the Role of Continuous Objective Monitoring (COM) Using Wearable Sensors

  2021cites this paper
• Current Knowledge on the Background, Pathophysiology, and Treatment of Levodopa-Induced Dyskinesia – Literature Review.

  2021cites this paper
• The impact of tube replacement timing during LCIG therapy on PEG-J associated adverse events: a retrospective multicenter observational study

  2021cites this paper
• Translating Evidence to Advanced Parkinson's Disease Patients: A Systematic Review and Meta‐Analysis

  2021cites this paper
• Guidelines for the Use of Parkinsonian Drugs (in USA)

  2020cites this paper
• Intrajejunal vs oral levodopa-carbidopa therapy in Parkinson disease

  2020cites this paper
• Continuous intestinal infusion of levodopa–carbidopa in patients with advanced Parkinson's disease in Spain: Subanalysis by autonomous community

  2019cites this paper
• Treatment of Parkinson's Disease after the Wearing Off Sets in

  2019cites this paper
• Comparison Between Levodopa-Carbidopa Intestinal Gel Infusion and Subthalamic Nucleus Deep-Brain Stimulation for Advanced Parkinson's Disease: A Systematic Review and Meta-Analysis

  2019cites this paper
• Endoscopic management of duodenal levodopa-carbidopa therapy of advanced Parkinson's disease.

  2019cites this paper
• Multicenter study of levodopa carbidopa intestinal gel in Parkinson’s disease: the Turkish experience

  2019cites this paper
• EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease

  2019cites this paper
• Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson’s disease

  2019cites this paper
• Technique and outcome of percutaneous endoscopic transgastric jejunostomy for continuous infusion of levodopa-carbidopa intestinal gel for treatment of Parkinson’s disease

  2019cites this paper
• Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson’s disease in patients in Scotland and Wales

  2018cites this paper
• Impact of Disease Duration in Effectiveness of Treatment with Levodopa-Carbidopa Intestinal Gel and Factors Leading to Discontinuation

  2018influential citation
• Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease: A Systematic Review and Meta-Analysis

  2018cites this paper
• Maximizing benefits of the levodopa/carbidopa intestinal gel: Systematic considerations, challenging convention and individualizing approaches

  2018cites this paper
• Rationale and patient selection for interventional therapies in Parkinson’s disease

  2018cites this paper
• Continuous intestinal infusion of levodopa-carbidopa in patients with advanced Parkinson's disease in Spain: Subanalysis by autonomous community.

  2018cites this paper
• Parkinson's disease: A review

  2018cites this paper
• Safety and Efficacy of Rotigotine for Treating Parkinson's Disease: A Meta-Analysis of Randomised Controlled Trials.

  2017cites this paper
• Problems related to levodopa‐carbidopa intestinal gel treatment in advanced Parkinson's disease

  2017influential citation
• Effects of levodopa/carbidopa intestinal gel versus oral levodopa/carbidopa on B vitamin levels and neuropathy

  2017cites this paper
• Levodopa-carbidopa enteral suspension in advanced Parkinson’s disease: clinical evidence and experience

  2017cites this paper
• Initiation of Levodopa-Carbidopa Intestinal Gel Infusion Using Telemedicine (Video Communication System) Facilitates Efficient and Well-Accepted Home Titration in Patients with Advanced Parkinson’s Disease

  2017cites this paper
• The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson’s disease

  2017cites this paper
• Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence?

  2017cites this paper
• Hallmarks of Treatment Aspects: Parkinson's Disease Throughout Centuries Including l-Dopa.

  2017cites this paper
• Duodenal Levodopa Infusion for Long-Term Deep Brain Stimulation–Refractory Symptoms in Advanced Parkinson Disease

  2017cites this paper
• Levodopa in Parkinson’s Disease: Current Status and Future Developments

  2017influential citation
• Patient Preferences for Device-Aided Treatments Indicated for Advanced Parkinson Disease.

  2017cites this paper
• Continuous intra jejunal infusion of levodopa-carbidopa intestinal gel by jejunal extension tube placement through percutaneous endoscopic gastrostomy for patients with advanced Parkinson's disease: a preliminary study.

  2016cites this paper
• Clinical management of patients with advanced Parkinson's disease treated with continuous intestinal infusion of levodopa/carbidopa.

  2016cites this paper
• Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia

  2016cites this paper
• Continuous intra jejunal infusion of levodopa-carbidopa intestinal gel by jejunal extension tube placement through percutaneous endoscopic gastrostomy for patients with advanced Parkinson ’ s disease : a preliminary study

  2016cites this paper
• Deep Brain Stimulation for Parkinson’s Disease with Early Motor Complications: A UK Cost-Effectiveness Analysis

  2016cites this paper
• Novel Levodopa Formulations for Parkinson’s Disease

  2016cites this paper
• Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson's disease.

  2016cites this paper
• Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes.

  2015cites this paper
• The effect of levodopa–carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson’s disease: a multicenter Romanian experience

  2015cites this paper
• Neurodegenerative diseases studied in human brain and rodent models

  2015cites this paper
• Carbidopa levodopa enteral suspension

  2015cites this paper
• Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program.

  2015cites this paper
• Novel formulations and modes of delivery of levodopa

  2015cites this paper
• A levodopa dry powder inhaler for the treatment of Parkinson's disease patients in off periods.

  2015cites this paper
• Initiation and dose optimization for levodopa-carbidopa intestinal gel: Insights from phase 3 clinical trials.

  2015cites this paper
• Validity and Responsiveness of At-Home Touch Screen Assessments in Advanced Parkinson's Disease

  2015cites this paper
• Asian perspectives on the recognition and management of levodopa ‘wearing-off’ in Parkinson’s disease

  2015cites this paper
• Levodopa-Carbidopa Intestinal Gel Infusion Therapy in Advanced Parkinson's Disease: Single Middle Eastern Center Experience

  2015cites this paper
• Evidence-based treatment of Parkinson's disease

  2015cites this paper
• Long-Term Treatment with Extended-Release Carbidopa–Levodopa (IPX066) in Early and Advanced Parkinson’s Disease: A 9-Month Open-Label Extension Trial

  2015cites this paper
• Impact of Pharmacotherapy on Quality of Life in Patients with Parkinson’s Disease

  2015cites this paper
• Effectiveness of Gastric Levodopa Infusion on Motor Fluctuations in a Series of Advanced Parkinson's Disease Cases

  2015cites this paper
• History and Perspectives of A2A Adenosine Receptor Antagonists as Potential Therapeutic Agents

  2015cites this paper
• Integrated safety of levodopa‐carbidopa intestinal gel from prospective clinical trials

  2015cites this paper
• Levodopa/carbidopa intestinal gel: an effective formulation for the management of advanced Parkinson's disease

  2015cites this paper
• Parkinson's Disease and Its Management: Part 4: Treatment of Motor Complications.

  2015cites this paper
• [Management of complications related to intraduodenal infusion of levodopa/carbidopa in patients with Parkinson's disease].

  2014cites this paper
• Phenomenology of Levodopa-Induced Dyskinesia

  2014cites this paper
• New Clinical Trials for Levodopa-Induced Dyskinesia

  2014cites this paper
• Pharmacological Treatment Options for Levodopa-Induced Dyskinesia

  2014cites this paper
• Treatment of motor fluctuations in Parkinson’s disease: recent developments and future directions

  2014cites this paper
• Pharmacological Properties of Levodopa

  2014cites this paper
• Parkinson’s disease: recent advances

  2014cites this paper
• Treatment of advanced Parkinson's disease.

  2014cites this paper
• Chapter 13 - Drugs that Affect Autonomic Functions or the Extrapyramidal System

  2014cites this paper
• Unwanted effects and interaction of intrajejunal levodopa/carbidopa administration

  2014cites this paper
• Peripheral neuropathy and parkinsonism: a large clinical and pathogenic spectrum

  2014cites this paper
• Clinical implications of irregular ADMET properties with levodopa and other antiparkinson's drugs

  2014cites this paper
• Dopamine agonist monotherapy in Parkinson's disease and potential risk factors for dyskinesia: a meta‐analysis of levodopa‐controlled trials

  2014cites this paper
• Parkinson disease: Intestinal levodopa infusion in PD—the first randomized trial

  2014cites this paper
• [The impact of levodopa-carbidopa intestinal gel on health-related quality of life in Parkinson's disease].

  2014cites this paper
• Mobile systems for monitoring Parkinson's disease

  2014cites this paper
• Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets

  2014cites this paper
• Wann sind Pflaster, Pens oder Pumpen eine sinnvolle Ergänzung zur oralen Therapie?

  2014cites this paper
• Emerging issues on selection criteria of levodopa carbidopa infusion therapy: considerations on outcome of 28 consecutive patients

  2014cites this paper
• Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson'd Disease: Final 12-Month, Open-Label Results

  2014cites this paper
• Profile of levodopa/carbidopa intestinal gel and its potential in the treatment of advanced Parkinson's disease

  2014cites this paper
• Levodopa in the Treatment of Parkinson's Disease: Current Status and New Developments

  2013cites this paper
• Études de la subthalamotomie comme traitement des dyskinésies chez le primate parkinsonien

  2013cites this paper
• The Management of Orthostatic Hypotension in Parkinson’s Disease

  2013influential citation
• Continuous dopaminergic delivery to minimize motor complications in Parkinson’s disease

  2013cites this paper
• Prevention and management of levodopa-related motor complications

  2013cites this paper
• Continuous Drug Delivery in Parkinson’s Disease

  2013cites this paper
• ANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATIO N OF CARBIDOPA, LEVODOPA AND ENTACAPONE IN ITS BULK AND TABLET DOSAGE FORM BY UPLC

  2013cites this paper